MINNEAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences:
UBS Global Healthcare Conference 2025
November 10, 2025
10:15 AM EST
Stifel 2025 Healthcare Conference
November 11, 2025
9:20 AM EST
Stephens Investment Conference
November 18, 2025
8:00 AM CST
Jefferies Global Healthcare Conference
November 20, 2025
12:30 PM GMT
A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: LinkedIn, X or YouTube.
Contact: | David Clair, Vice President, Investor Relations & Corporate Development |
This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$59.19 |
| Daily Change: | -0.06 -0.10 |
| Daily Volume: | 348,308 |
| Market Cap: | US$9.220B |
December 23, 2025 December 11, 2025 December 09, 2025 November 25, 2025 November 18, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
